Literature DB >> 33570639

Plasma fibrinolysis, inflammatory markers, and postthrombotic syndrome: preliminary findings from the Kids-DOTT Biobank.

Marisol Betensky1,2, Ernest K Amankwah3,4, Stephanie Brandal5, Allen D Everett5, Neil A Goldenberg1,4,6.   

Abstract

Plasma levels of markers of coagulation and inflammation have been identified as prognostic factors for adult postthrombotic syndrome (PTS). We aimed to determine whether plasma fibrinolytic capacity and cytokine levels during the first 3 months after provoked deep venous thrombosis (DVT) are associated with risk of PTS in young patients. We analyzed plasma biospecimens (6 weeks and 3 months after provoked DVT) and clinical data from a National Heart, Lung, and Blood Institute-sponsored multinational trial of anticoagulation for provoked venous thromboembolism in patients younger than age 21 years (Kids-DOTT). Patients with a provoked extremity DVT who had plasma samples available at both 6-week and 3-month post-DVT time points and PTS assessment at 1 year were included. We measured plasma fibrinolytic capacity using the Clot Formation and Lysis (CloFAL) assay and plasma cytokine levels by multiplex immunoassay. Logistic regression analyses evaluated prognostic associations with PTS. Seventy-nine patients were included (median age, 12.8 years; range, 0.04-20.8 years). PTS developed in 34%. Complete veno-occlusion at 6 weeks after diagnosis of DVT (odds ratio [OR], 3.12; 95% confidence interval [CI], 0.81-11.94; P = .097), low fibrinolytic capacity in plasma at 3 months post-DVT (OR, 2.71; 95% CI, 0.92-7.97; P = .07), and elevated serum amyloid A at 3 months post-DVT (OR, 2.85; 95% CI, 0.98-8.34; P = .055) were identified as putative prognostic factors for development of PTS. In multivariable logistic regression analysis, these factors did not retain a statistically significant independent association with PTS, but these preliminary results warrant further investigation in an independent data set to definitively evaluate these findings and identify additional potential prognostic factors for the development of PTS after a provoked DVT in young patients.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33570639      PMCID: PMC7805334          DOI: 10.1182/bloodadvances.2020002974

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  22 in total

1.  Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome.

Authors:  A C Bouman; J J M Smits; H Ten Cate; A J Ten Cate-Hoek
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

2.  A new global assay of coagulation and fibrinolysis.

Authors:  Neil A Goldenberg; William E Hathaway; Linda Jacobson; Marilyn J Manco-Johnson
Journal:  Thromb Res       Date:  2005-01-20       Impact factor: 3.944

3.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  The predictive value of markers of fibrinolysis and endothelial dysfunction in the post thrombotic syndrome. A systematic review.

Authors:  Anat Rabinovich; Jacqueline M Cohen; Susan R Kahn
Journal:  Thromb Haemost       Date:  2014-02-06       Impact factor: 5.249

5.  Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome.

Authors:  J Siudut; M Grela; E Wypasek; K Plens; A Undas
Journal:  J Thromb Haemost       Date:  2016-02-18       Impact factor: 5.824

6.  Monitoring hypercoagulability and hypofibrinolysis following acute venous Thromboembolism in children: application of the CloFAL assay in a prospective inception cohort study.

Authors:  Christopher Bombardier; Elizabeth Villalobos-Menuey; Katherine Ruegg; William E Hathaway; Marilyn J Manco-Johnson; Neil A Goldenberg
Journal:  Thromb Res       Date:  2012-04-30       Impact factor: 3.944

7.  Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.

Authors:  N A Goldenberg; T Abshire; P J Blatchford; L Z Fenton; J L Halperin; W R Hiatt; C M Kessler; J M Kittelson; M J Manco-Johnson; A C Spyropoulos; P G Steg; N V Stence; A G G Turpie; S Schulman
Journal:  J Thromb Haemost       Date:  2015-08-11       Impact factor: 5.824

8.  Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway.

Authors:  Katri Niemi; Laura Teirilä; Jani Lappalainen; Kristiina Rajamäki; Marc H Baumann; Katariina Öörni; Henrik Wolff; Petri T Kovanen; Sampsa Matikainen; Kari K Eklund
Journal:  J Immunol       Date:  2011-04-20       Impact factor: 5.422

9.  Serum amyloid A induces monocyte tissue factor.

Authors:  Hong Cai; Changjie Song; Ikuko Endoh; Jesse Goyette; Wendy Jessup; S Ben Freedman; H Patrick McNeil; Carolyn L Geczy
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

10.  Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children.

Authors:  Neil A Goldenberg; R Knapp-Clevenger; Marilyn J Manco-Johnson
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

View more
  1 in total

1.  Characteristics of upper- and lower-extremity deep vein thrombosis and predictors of postthrombotic syndrome in children.

Authors:  Laura Avila; Nour Amiri; Riddhita De; Jennifer Vincelli; Eleanor Pullenayegum; Suzan Williams; Leonardo R Brandão
Journal:  Blood Adv       Date:  2021-10-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.